Non alcoholic fatty liver disease: A new risk factor for cardiovascular disease?

##plugins.themes.academic_pro.article.sidebar##

Published Apr 3, 2013
Download
pdf
Vol. 91 No. 3 (2013): Issue Mar 2013

##plugins.themes.academic_pro.article.main##

Wissem Sdiri
Hayfa Romdhane
Service de Gastro-entérologie A. Hôpital la Rabta. Tunis
Dorra Mbarek
Hatem Ben Abdallah
Selma Longo
Mohamed Nabil Abdelli
Mohamed Rachid Boujnah

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is frequently diagnosed in daily practice. This condition is represented by a large spectrum of chronic liver diseases going from pure hepatic steatosis to cirrhosis and its complications, including hepatocellular carcinoma. NAFLD is usually associated to glucose and lipoproteins metabolism increasing the cardiovascular risk.
aim: To review new advances in the knowledge of the pathophysiological links between NAFLD and cardiovascular risk, evaluation of cardiovascular risk in this special situation and the different therapeutics proposed.
methods: Systematic review of the literature using medical data bases (Medline) with the following key words: non-alcoholic fatty liver disease, hepatic steatosis, cardiovascular risk, metabolic syndrome.
results: We’ll report pathophysiological links between NAFLD and cardiovascular risk, propose an evaluation of cardiovascular risk in this special situation and expose a therapeutic strategy.
Conclusion: The discovery of a non alcoholic fatty liver disease should lead to a cardiovascular risk evaluation.

Keywords:

Non-alcoholic fatty liver disease, hepatic steatosis, cardiovascular risk, metabolic syndrome

##plugins.themes.academic_pro.article.details##

References

  1. Lemoine M. Stéatopathie métabolique : définition et histoire biologique. Gastroenterol Clin Biol 2009; 33:398-404.
  2. Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis. 2007; 17:684- 98.
  3. Targher G, Arcaro G. Nonalcoholic fatty liver disease and increased risk of cardiovascular disease. Artherosclerosis 2007;191: 235-40.
  4. JAY SIWEK, MARGARET L. GOURLAY, David C et al. How to write an Evidence-Based Clinical Review Article. Am Fam Physician. 2002; 65:251-58.
  5. O'Leary DH, Polak JF, Kronmal RA et al. distribution and correlates of sonographically detected carotid artery disease in the cardiovascular health study. The CHS collaborative research group. Stroke 1992;23:1752-60.
  6. Targher G, Bertolini L, Padovani R et al. relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes care 2006;29:1325-30.
  7. Villanova N, Moscatiello S, Ramilli S et al. endothelial dysfunction and cardiovascular risk profile in non-alcoholic fatty liver disease. Hepatology 2005;42: 473-78.
  8. Targher G, Bertolini L, Padovani R et al. increased prevalence of cardiovascular disease among type 2 diabetic patients with nonalcoholic fatty liver disease. Diabet Med 2006; 23: 403-9.
  9. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischaemic heart disease. World J Gastroenterol 2005;11: 4838-42.
  10. Kessler A, Levy Y, Roth A. et al. increased prevalence of NAFLD in patients with acute myocardial infarction independent of BMI. Hepatology 2005;42;623A [Abstract]
  11. Schwimmer JB, Deutsch R, Behling C, Lavine JE. Fatty liver as a determinant of atherosclerosis. Hepatology 2005;42:610A [Abstract]
  12. Adams LA, Lymp JF, St Sauver J et al. the natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
  13. Wannawethee G, Ebrahim S, Shaper AG. Gamma-glutamyl transferase: determinants and association with mortality from ischaemic heart disease and all causes. Am J epidemiol 1995;142: 699-708
  14. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006;43:1145-51.
  15. Ruttmann E, Brant LJ, Concin H et al. gamma-glutamyl transferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a chort of 163 944 austrian adults. Circulation 2005;112:2130-37.
  16. Yki-Jarvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Mol Med 2005;5:287-95.
  17. Nannipieri M, Gonzales C, Baldi S et al. liver enzymes, the metabolic syndrome and incident diabetes. The Mexico city diabetes study. Diabetes care 2005;28:1757-62.
  18. Targher G, Bertolini L, Scala L et al. non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non diabetic men. Role of visceral adipose tissue. Diabetes Med 2005;22:1354-58.
  19. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb vasc biol. 2004; 24:29-33.
  20. Targher G, Bertolini L, Zenari L. Hypoadiponectinemia is closely associated with non-alcoholic hepatic steatosis in obese subjects. Diabetes care 2004; 27: 2085-86.
  21. Charlton M, Sreekumar R, Rasmusserm D, Lindor K, Nair KS. Alpolipoprotein synthesis in non-alcoholic steatohepatitis. Hepatology 2002;35:898-904.
  22. Loria P, Adinolfi LE, Bellantini S et al. practice guidelines for the diagnosis and management of non-alcoholic fatty liver disease. A Decalogue from the Italian association for the study of the liver (AISF) expert committee. Dig Liver Dis 2010;42:272-82.